Please enable JavaScript or talk to your local administrator to get JavaScript enabled.
Skip filters
Skip facets
Funder
  • 260

  • 129

  • 31

  • 30

  • 29

  • 28

  • 26

  • 25

  • 19

  • 15

Funder Group
Research Organization
FOR (ANZSRC) Category
RCDC Category
Researcher
City
State
Country
Country of Funder
Start Year
Active Year
Similar Projects for

Project

BIOMARKERS FOR BLADDER CANCER CHEMOPREVENTION TRIALS

Funder: National Cancer Institute

Funding period
0
Funding amount
Abstract
DESCRIPTION: Bladder cancer remains an important public-health problem with more 54,000 individuals predicted to be diagnosed in 1997. Despite important advances, approximately one half of the patients diagnosed with superficial disease will suffer a recurrence, and these patients have a significant risk for developing muscle invasive disease. Cystectomy is generally required for muscle invasive disease. Identification of individuals at high risk for recurrence and progression is thus critical, but current clinical markers are imperfect. Prevention of the dire consequences of disease progression is an even more desirable goal. To this end, a number of putative chemopreventive agents have been identified. Clinical investigation and development of these agents is, however, limited by lack of markers to determine efficacy. Thus, th purpose of this proposal is to identify and develop markers based on the known disease biology that may be intermediate markers for chemoprevention studies. Three such markers will be evaluated here. The first is deletion of the 9p21 chromosomal region as determined by fluorescence in situ hybridization (FISH). These deletions are the most common and earliest identifiable genetic alteration in bladder cancer. The second is overexpression of the epidermal growth factor receptor (EGFR). Such overexpression has been identified in the histologically normal tissue of patients with bladder cancer. The final marker is 8-OH-deoxyguanosine (8-OHdG). This marker of oxidative DNA damage has been reported to be elevated in the urine of tobacco abusers, and bladder cancer is a tobacco-related disease. The eventual goal is to develop markers that are easily measured in the urine or in bladder wash specimens. In this proposal, measurements for each marker will be determined in such samples and compared to measurements in normal and malignant tissue from the same patient. In this manner any abnormal findings will be validated. Marker measurements will then be performed in individuals who have had a superficial tumor resected and are being followed for disease recurrence. Any detectable abnormalities at the time when no clinical disease is identifiable will be correlated with the risk of recurrence and marker findings at the time of recurrence.

 
771
Projects
USD 417.1 M
Aggregated funding amount
USD 720 K
Average funding amount
Project list item
Intravesical delivery of an Fc-enhanced CD40 agonist antibody for the treatment of bladder cancer

Bladder Cancer Advocacy Network to Jeffrey Ravetch, David Knorr

USD 300,000
2020 - 2022
Project list item
Epigenetic regulators of subtype plasticity in bladder cancer

Bladder Cancer Advocacy Network to John Robert Christin

USD 1,700
2020 - 2020
Project list item
Defining NRF2 induced tumor invasion in bladder cancer

Bladder Cancer Advocacy Network to Yuki Kita, William Youngkwan Kim, Bernard Weissman

USD 50,000
2020 - 2021
Project list item
Alpha1H: A Unique Bladder Cancer Therapeutic, Acting with Great Precision

European Commission

USD 2,452,885
2020 - 2022
Project list item
Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer

National Cancer Institute to NINA BHARDWAJ, JUN ZHU, MATTHEW GALSKY

USD 703,400
2020 - 2025
Project list item
SGLT-2 Inhibitors and Early Bladder Cancer Events: An International Multi-Centre Study

Canadian Institutes of Health Research to Elisabetta Patorno, Laurent Azoulay, Devin Abrahami, Lysanne Campeau, Blanaid Hicks, Robert William Platt, Sebastian Schneeweiss, Oriana Hoi Yun Yu

USD 88,269
2020 - 2022
Project list item
Implication of neutrophil extracellular traps in the efficacy of bladder-sparing therapy in muscle invasive bladder cancer

Canadian Institutes of Health Research to Wassim Kassouf, Ciriaco A. Piccirillo, Jonathan David Spicer

USD 138,878
2020 - 2025
Project list item
Chimeric RNAs and their implication in lymphatic metastasis of bladder cancer

National Cancer Institute to HUI LI

USD 205,913
2020 - 2025
Project list item
CD40 agonism for the treatment of bladder cancer

National Cancer Institute to CHRISTOPHER STUART GARRIS

USD 64,554
2020 - 2023
Project list item
Analysis of the effect of IDO inhibition on activation of the aryl hydrocarbon receptor pathway in bladder cancer

São Paulo Research Foundation to Humberto Dellê

 
2020 - 2021
Project list item
A new bladder cancer model based on tissue reprogramming and gene targeting

National Cancer Institute to FLAMINIA TALOS, DAIFENG WANG

USD 203,843
2020 - 2021
Project list item
Identification and analysis of early prognostic markers of bladder cancer using generated nanobodies

Russian Science Foundation to Sergei Tillib

 
2020 - 2022
Project list item
Roles of epigenetic regulators in bladder cancer progression

University of California - Cancer Research Coordinating Committee to Zhu Wang

USD 74,960
2020 - 2020
Project list item
Quantifying Risk and Resilience (R2) among Patients with Bladder Cancer: A Novel Personalized, Comprehensive Risk Stratification Program

Bladder Cancer Advocacy Network to Sarah Psutka, Jonathan Wright, Daniel Lin, John Gore, Ryan O'Malley, Anne Browning, Florian Fintelmann

USD 50,000
2020 - 2021
Project list item
Platform Selection for Biomarker Directed Radiotherapy for Bladder Cancer

NIHR Evaluation Trials and Studies Coordinating Centre to Catharine West

USD 51,871
2020 - 2020
Project list item
A canine model for human high-risk non-muscle invasive human bladder cancer – molecular and environmental considerations.

V Foundation for Cancer Research to Matthew Breen

USD 500,000
2019 - 2021
Project list item
Chemotherapy plus PD-1 blockade as bladder-sparing treatment for muscle-invasive bladder cancer

V Foundation for Cancer Research to Matthew D Galsky

USD 600,000
2019 - 2022
Project list item
Unravelling Mechanisms of Resistance to Checkpoint Inhibition in Canine Urothelial Carcinoma

V Foundation for Cancer Research to Nicola J. Mason

USD 500,000
2019 - 2021
Project list item
Engineering Smart Solutions for Disorders of the Bladder Urothelium

Engineering and Physical Sciences Research Council

 
2019 - 2023
load more...